BACKGROUND: We have previously reported a relationship between increased airway responsiveness (AR) in infancy and reduced childhood lung function. OBJECTIVE: The current study aimed to determine whether the Arg16Gly polymorphism of the beta2 adrenoceptor (beta2AR) gene was important to this relationship. METHODS: A cohort that initially numbered 253 individuals underwent assessments of AR and lung function aged 1 month, 6 and 11 years; genotyping for polymorphisms of the beta(2)AR was performed. RESULTS: At 1 month of age, the genotype homozygous Arg16 (n=24) was associated with a mean increase in log dose-response slope (AR) of 0.27 [95% confidence interval (CI) 0.07, 0.49] compared with the genotype homozygous Gly16 (n=58), P=0.01. At 11 years of age, the genotype homozygous Arg16 (n=35) was associated with a mean reduction in the percentage of forced expiratory volume in 1 s of 5.3% [95% CI 0.3, 10.2] compared with the genotype homozygous Gly16 (n=65), P=0.03. There was no association between the Arg16Gly polymorphism and atopy or diagnosed asthma. However, nine of 69 individuals with the genotype homozygous Gly16 were admitted to hospital with asthma compared with five out of 111 individuals with the remaining genotypes (P<0.05). CONCLUSION: The Arg16Gly polymorphism may be important to the association between increased AR in infancy and reduced lung function in childhood and may also be a determinant of asthma severity in children but not asthma per se.
BACKGROUND: We have previously reported a relationship between increased airway responsiveness (AR) in infancy and reduced childhood lung function. OBJECTIVE: The current study aimed to determine whether the Arg16Gly polymorphism of the beta2 adrenoceptor (beta2AR) gene was important to this relationship. METHODS: A cohort that initially numbered 253 individuals underwent assessments of AR and lung function aged 1 month, 6 and 11 years; genotyping for polymorphisms of the beta(2)AR was performed. RESULTS: At 1 month of age, the genotype homozygous Arg16 (n=24) was associated with a mean increase in log dose-response slope (AR) of 0.27 [95% confidence interval (CI) 0.07, 0.49] compared with the genotype homozygous Gly16 (n=58), P=0.01. At 11 years of age, the genotype homozygous Arg16 (n=35) was associated with a mean reduction in the percentage of forced expiratory volume in 1 s of 5.3% [95% CI 0.3, 10.2] compared with the genotype homozygous Gly16 (n=65), P=0.03. There was no association between the Arg16Gly polymorphism and atopy or diagnosed asthma. However, nine of 69 individuals with the genotype homozygous Gly16 were admitted to hospital with asthma compared with five out of 111 individuals with the remaining genotypes (P<0.05). CONCLUSION: The Arg16Gly polymorphism may be important to the association between increased AR in infancy and reduced lung function in childhood and may also be a determinant of asthma severity in children but not asthma per se.
Authors: Melanie C Matheson; Justine A Ellis; Joan Raven; David P Johns; E Haydn Walters; Michael J Abramson Journal: J Hum Genet Date: 2006-09-01 Impact factor: 3.172
Authors: Gregory A Hawkins; Kelan Tantisira; Deborah A Meyers; Elizabeth J Ampleford; Wendy C Moore; Barbara Klanderman; Stephen B Liggett; Stephen P Peters; Scott T Weiss; Eugene R Bleecker Journal: Am J Respir Crit Care Med Date: 2006-08-24 Impact factor: 21.405
Authors: Stephen W Turner; Jon G Ayres; Tatiana V Macfarlane; Anil Mehta; Gita Mehta; Colin N Palmer; Steve Cunningham; Tim Adams; Krishnan Aniruddhan; Claire Bell; Donna Corrigan; Jason Cunningham; Andrew Duncan; Gerard Hunt; Richard Leece; Una MacFadyen; Jonathan McCormick; Sally McLeish; Andrew Mitra; Deborah Miller; Elizabeth Waxman; Alan Webb; Slawomir Wojcik; Somnath Mukhopadhyay; Donald Macgregor Journal: BMC Med Res Methodol Date: 2010-12-06 Impact factor: 4.615
Authors: Steve Turner; Ben Francis; Susanne Vijverberg; Maria Pino-Yanes; Anke H Maitland-van der Zee; Kaninika Basu; Lauren Bignell; Somnath Mukhopadhyay; Roger Tavendale; Colin Palmer; Daniel Hawcutt; Munir Pirmohamed; Esteban G Burchard; Brian Lipworth Journal: J Allergy Clin Immunol Date: 2016-01-07 Impact factor: 10.793